NasdaqGS:AZTALife Sciences
The Bull Case For Azenta (AZTA) Could Change Following Lowered 2026 Outlook And Multiomics Overhaul – Learn Why
In Q2 2026, Azenta reported a 3% organic revenue decline, compressed adjusted EBITDA margins, and lowered its full-year organic revenue guidance to a range of 2% decline to 1% growth, citing softer North American demand and capital spending constraints.
The company also announced leadership changes, including appointing Trey Martin as President of Multiomics and advancing the integration of UK Biocentre to support a broader transformation of its multiomics and European operations.
We’ll now...